GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arrowhead Pharmaceuticals Inc (NAS:ARWR) » Definitions » Price-to-Tangible-Book

ARWR (Arrowhead Pharmaceuticals) Price-to-Tangible-Book : 3.86 (As of Jul. 09, 2025)


View and export this data going back to 1995. Start your Free Trial

What is Arrowhead Pharmaceuticals Price-to-Tangible-Book?

As of today (2025-07-09), Arrowhead Pharmaceuticals's share price is $18.88. Arrowhead Pharmaceuticals's Tangible Book per Share of Mar. 2025 for the quarter that ended in Mar. 2025 was $4.89. Hence, Arrowhead Pharmaceuticals's Price to Tangible Book Ratio of today is 3.86.

The historical rank and industry rank for Arrowhead Pharmaceuticals's Price-to-Tangible-Book or its related term are showing as below:

ARWR' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.52   Med: 9.37   Max: 53.11
Current: 3.86

During the past 13 years, Arrowhead Pharmaceuticals's highest Price to Tangible Book Ratio was 53.11. The lowest was 1.52. And the median was 9.37.

ARWR's Price-to-Tangible-Book is ranked worse than
56.63% of 1199 companies
in the Biotechnology industry
Industry Median: 2.96 vs ARWR: 3.86

A closely related ratio is called PB Ratio. As of today, Arrowhead Pharmaceuticals's share price is $18.88. Arrowhead Pharmaceuticals's Book Value per Sharefor the quarter that ended in Mar. 2025 was $4.95. Hence, Arrowhead Pharmaceuticals's P/B Ratio of today is 3.81.


Arrowhead Pharmaceuticals Price-to-Tangible-Book Historical Data

The historical data trend for Arrowhead Pharmaceuticals's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arrowhead Pharmaceuticals Price-to-Tangible-Book Chart

Arrowhead Pharmaceuticals Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Price-to-Tangible-Book
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.83 9.87 16.48 9.06 11.04

Arrowhead Pharmaceuticals Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Price-to-Tangible-Book Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.48 10.04 13.62 53.11 2.60

Competitive Comparison of Arrowhead Pharmaceuticals's Price-to-Tangible-Book

For the Biotechnology subindustry, Arrowhead Pharmaceuticals's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arrowhead Pharmaceuticals's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arrowhead Pharmaceuticals's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Arrowhead Pharmaceuticals's Price-to-Tangible-Book falls into.


;
;

Arrowhead Pharmaceuticals Price-to-Tangible-Book Calculation

Arrowhead Pharmaceuticals's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book=Share Price/Tangible Book per Share (Q: Mar. 2025 )
=18.88/4.894
=3.86

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.


Arrowhead Pharmaceuticals Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Arrowhead Pharmaceuticals's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.


Arrowhead Pharmaceuticals Business Description

Traded in Other Exchanges
Address
177 E Colorado Boulevard, Suite 700, Pasadena, CA, USA, 91105
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.
Executives
Christopher Richard Anzalone director, officer: President and CEO ARROWHEAD RESEARCH CORPORATION, 201 SOUTH LAKE AVENUE, SUITE 703, PASADENA CA 91101
Adeoye Y Olukotun director 3621 SOUTH STATE ST, 695 KMS PL, ANN ARBOR MI 48108
Kenneth Allen Myszkowski officer: CFO ARROWHEAD RESEARCH CORPORATION, 201 SOUTH LAKE AVENUE, SUITE 703, PASADENA CA 91101
Patrick O'brien officer: General Counsel 225 S. LAKE AVENUE SUITE 1050, PASADENA CA 91101
James C Hamilton other: Senior Vice President 177 EAST COLORADO BLVD, SUITE 700, PASADENA CA 91105
William D. Waddill director C/O CALITHERA BIOSCIENCES, 343 OYSTER POINT BLVD, SUITE 200, SO. SAN FRANCISCO CA 94080
Douglas B Given director C/O NEORX CORP, 410 WEST HARRISON ST, SEATTLE WA 98119
Victoria Vakiener director C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Tracie Oliver officer: Chief Commercial Officer 177 E COLORADO BLVD, SUITE 700, PASADENA CA 91105
Mauro Ferrari director 201 SOUTH LAKE AVENUE, PASADENA CA 91101
Martin Javier San officer: Chief Medical Officer 177 E COLORADO BLVD, STE 700, PASADENA CA 91105
Michael S Perry director C/O BIOTRANSPLANT INC, 196 BOSTON AVE SUITE 2800, MEDFORD MA 02155
Backer Marianne De director 177 E COLORADO BLVD, SUITE 700, PASADENA CA 91105
James Hassard officer: Chief Commercial Officer 177 E COLORADO BLVD, STE 700, PASADENA CA 91105
Curt Bradshaw officer: Chief Scientific Officer 177 E COLORADO BLVD, STE 700, PASADENA CA 91105